Logo

Astellas and Seagen Report EMA's Acceptance of MAA for Enfortumab Vedotin to Treat Locally Advanced or Metastatic Urothelial Cancer

Share this

Astellas and Seagen Report EMA's Acceptance of MAA for Enfortumab Vedotin to Treat Locally Advanced or Metastatic Urothelial Cancer

Shots:

  • The MAA is based on the P-III EV-301 trial which involves assessing Enfortumab Vedotin vs CT in ~ 600 patients with LA/m-UC- prior treated with Pt.-based CT and a PD-1/L1 inhibitor
  • The 1EPs of the trial is OS and 2EPs include PFS- ORR- DoR- DCR as well as the assessment of safety/tolerability and QoL parameters
  • If approved- Enfortumab Vedotin will be the 1st ADC available in the EU for UC. The MAA requests review of Enfortumab Vedotin under accelerated assessment for LA/M-UC

 ­ Ref: BusinessWire | Image: Astellas

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions